Robyn Karnauskas
Stock Analyst at Truist Securities
(2.43)
# 2,561
Out of 5,090 analysts
178
Total ratings
44.08%
Success rate
0.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,008.61 | +17.19% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.56 | +180.90% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $332.52 | -10.38% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $52.37 | +24.12% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $100.07 | +9.92% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $121.38 | -31.62% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $226.54 | -7.30% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.20 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $182.61 | +86.19% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.36 | +1,811.76% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.22 | +476.13% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $722.63 | +57.07% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.95 | +414.14% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.54 | +154.60% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $21.10 | +9.00% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $22.66 | +111.87% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $25.40 | +96.85% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $455.93 | +11.42% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.99 | +38.51% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $77.37 | -67.69% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.07 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $53.01 | +164.10% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $4.34 | +691,144.24% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.08 | +548.15% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $20.77 | +164.81% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $11.00 | +2,810.41% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $24.37 | -38.45% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.22 | +38,536.36% | 1 | Oct 8, 2020 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,008.61
Upside: +17.19%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.56
Upside: +180.90%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $332.52
Upside: -10.38%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $52.37
Upside: +24.12%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $100.07
Upside: +9.92%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $121.38
Upside: -31.62%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $226.54
Upside: -7.30%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.20
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $182.61
Upside: +86.19%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.36
Upside: +1,811.76%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.22
Upside: +476.13%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $722.63
Upside: +57.07%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.95
Upside: +414.14%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.54
Upside: +154.60%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $21.10
Upside: +9.00%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $22.66
Upside: +111.87%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $25.40
Upside: +96.85%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $455.93
Upside: +11.42%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.99
Upside: +38.51%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $77.37
Upside: -67.69%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.07
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $53.01
Upside: +164.10%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $4.34
Upside: +691,144.24%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.08
Upside: +548.15%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $20.77
Upside: +164.81%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $11.00
Upside: +2,810.41%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $24.37
Upside: -38.45%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.22
Upside: +38,536.36%